<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Bergenstal, Richard</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Insulin Analogs</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">The basal insulin analog LY2605541 (LY) is a long-acting, PEGylated insulin lispro that is designed with a large hydrodynamic size, which delays insulin absorption and reduces clearance, resulting in prolonged duration of action. LY demonstrates a preferential hepatic effect compared with human insulin in a somatostatin-infused/glucagon-replaced conscious dog model [Moore MC et al. ADA 2012 Abstract 1609P]. This article discusses data that showed that in a continuously glucose-monitored cohort of patients with type 2 diabetes mellitus, those receiving LY had lower intra-day glucose variability and fewer and shorter episodes of hypoglycemia compared with patients receiving glargine.</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>